Study of HS-10370 for advanced cancers with KRAS G12C
Treatments studied
Part of Cancer clinical trials.
This trial tests HS-10370, a new targeted medicine, in people with advanced solid tumors that cannot be treated with standard options. It focuses on cancers that have a specific change in the KRAS gene (KRAS G12C).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or older
- You have advanced or metastatic solid cancer, and standard treatment is not possible, not available, or not tolerated
- Your tumor test must show the KRAS G12C mutation (this is checked using a tissue sample by a study lab)
- You must have at least one measurable tumor spot on scans
- Your general functioning must be fairly good (ECOG 0 to 1) and you must be expected to live more than 12 weeks
- You must be able to use effective birth control during the study and for 6 months after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
This trial tests a combination of two experimental drugs (SY-5933 and CT-707) for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the combination is safe and effective.
This trial tests a new drug called HS-20105 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug (HS-10370) combined with other cancer treatments for people with advanced lung cancer that has a specific mutation called KRAS G12C. It is for those who have not yet received systemic therapy for their advanced disease.
This trial tests a new drug (HS-10370) in combination with other cancer treatments for people with advanced solid tumors that have a specific genetic change (KRAS G12C). It's for patients who have tried standard options without success.
This study tests a new drug called HS-10541 that targets a specific genetic change (KRAS G12C mutation) found in some advanced cancers. The drug may be given alone or combined with other cancer treatments to see if it can slow or shrink tumors.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.